Lakefront Biotherapeutics reported EUR1.72M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
argenx SE USD 1000K 0 Sep/2026
AstraZeneca USD 371M 31M Sep/2026
Biogen USD 72.6M 12.6M Jun/2025
Genmab DKK 139M 129M Jun/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
Incyte USD 605K 23K Sep/2026
Merck EUR 119M 18M Sep/2026
Neurocrine Biosciences USD 300K 2.6M Sep/2026
Novartis USD 468M 6M Sep/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 222M 65M Sep/2026
UCB EUR 49M 29M Dec/2025
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026